Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PTC Therapeutics, Inc. (PTCT)
USD79.85
-1.49 (-1.83%)
US NASDAQ Healthcare Biotechnology
Address
100 Corporate Court 7080
Warren, NJ, US
Warren, NJ, US
CEO
Matthew Klein
Website
ptcbio.com
IPO
2013-06-20
CIK 1070081 ISIN US69366J2006
Description
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
News Sentiment (7d)
3 articles
- PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD79.85
-1.49 (-1.83%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.53
Float Shares
73.00M
Free Float %
88.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.38% | +13.51% | +9.22% | +6.11% | +0.09% | -1.24% | +63.05% | +37.20% | +95.93% | +1,036.67% | +354.94% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (26 ratings, all time)
Buy
Price Targets & DCF
Current price
79.85
Low
82.00
+2.7%
Consensus
98.00
+22.7%
Median
94.00
+17.7%
High
120.00
+50.3%
Ratings Trend (MoM)
60% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 5 | 0 |
| Hold | 5 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
108.00
+35.3%
|
| Last Quarter | 5 |
97.60
+22.2%
|
| Last Year | 13 |
88.15
+10.4%
|
| All Time | 26 |
67.04
-16.0%
|
Quality scores
Altman Z-Score
0.57
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+114.5% ★ Q1'26: -76.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+264.5% ★ Q1'26: -100.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+38.1% Q1'26: -22.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+49.1% ★ Q1'26: +16.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: -10.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+14.9% Q1'26: -4.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.55× ★ Q1'26: 1.61× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 8 EPS Ana. |
Dec 2027 10 Rev. Ana. 8 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
22.96M
est: 22.75M (+0.9%)
|
36.77M
est: 37.07M (-0.8%)
|
82.71M
est: 81.76M (+1.2%)
|
194.39M
est: 190.59M (+2.0%)
|
264.73M
est: 263.75M (+0.4%)
|
306.98M
est: 305.90M (+0.4%)
|
380.77M
est: 376.02M (+1.3%)
|
538.59M
est: 524.98M (+2.6%)
|
698.80M
est: 716.43M (-2.5%)
|
937.82M
est: 900.45M (+4.1%)
|
806.78M
est: 803.68M (+0.4%)
|
1.73B
est: 1.85B (-6.3%)
|
1.11B
891.42M – 1.22B
-40.1% YoY
|
1.26B
1.05B – 1.57B
+14.0% YoY
|
1.49B
1.46B – 1.51B
+17.7% YoY
|
1.68B
1.28B – 2.00B
+13.1% YoY
|
1.82B
1.39B – 2.17B
+8.6% YoY
|
| EBITDA |
-97.18M
est: -87.05M (-11.6%)
|
-164.25M
est: -155.63M (-5.5%)
|
-128.77M
est: -41.00M (-214.0%)
|
-46.61M
est: -95.58M (+51.2%)
|
-89.47M
est: -86.68M (-3.2%)
|
-195.26M
est: -153.41M (-27.3%)
|
-303.09M
est: -369.86M (+18.1%)
|
-368.18M
est: -306.27M (-20.2%)
|
-367.78M
est: -259.37M (-41.8%)
|
-330.34M
est: -215.85M (-53.0%)
|
-120.46M
est: -192.65M (+37.5%)
|
887.66M
est: -442.93M (+300.4%)
|
-265.43M
-293.50M – -213.68M
+40.1% YoY
|
-302.52M
-375.22M – -250.93M
-14.0% YoY
|
-356.02M
-360.94M – -351.11M
-17.7% YoY
|
-402.66M
-478.55M – -306.09M
-13.1% YoY
|
-437.36M
-519.80M – -332.47M
-8.6% YoY
|
| EBIT |
-99.41M
est: -89.88M (-10.6%)
|
-167.13M
est: -156.13M (-7.0%)
|
-132.06M
est: -53.49M (-146.9%)
|
-64.29M
est: -124.69M (+48.4%)
|
-115.56M
est: -99.17M (-16.5%)
|
-227.44M
est: -200.13M (-13.6%)
|
-346.58M
est: -1.03B (+66.2%)
|
-432.32M
est: -317.08M (-36.3%)
|
-496.62M
est: -257.47M (-92.9%)
|
-566.93M
est: -336.86M (-68.3%)
|
-196.13M
est: -300.65M (+34.8%)
|
848.85M
est: -691.24M (+222.8%)
|
-414.23M
-458.05M – -333.48M
+40.1% YoY
|
-472.12M
-585.57M – -391.60M
-14.0% YoY
|
-555.62M
-563.28M – -547.95M
-17.7% YoY
|
-628.39M
-746.84M – -477.69M
-13.1% YoY
|
-682.55M
-811.21M – -518.86M
-8.6% YoY
|
| Net Income |
-93.75M
est: -84.43M (-11.0%)
|
-170.45M
est: -158.75M (-7.4%)
|
-142.11M
est: -337.96M (+58.0%)
|
-79.00M
est: -164.70M (+52.0%)
|
-128.08M
est: -111.53M (-14.8%)
|
-251.58M
est: -240.94M (-4.4%)
|
-438.16M
est: -1.21B (+63.9%)
|
-523.90M
est: -436.99M (-19.9%)
|
-559.02M
est: -398.38M (-40.3%)
|
-626.60M
est: -479.52M (-30.7%)
|
-363.30M
est: -372.18M (+2.4%)
|
682.64M
est: 682.64M (+0.0%)
|
9.36M
-2.89M – 21.62M
-98.6% YoY
|
79.61M
-156.36M – 315.39M
+750.2% YoY
|
134.62M
-66.58M – 393.71M
+69.1% YoY
|
331.46M
228.12M – 412.68M
+146.2% YoY
|
423.75M
291.63M – 527.58M
+27.8% YoY
|
| SGA |
44.82M
est: 10.78M (+315.9%)
|
82.08M
est: 17.56M (+367.4%)
|
97.13M
est: 38.73M (+150.8%)
|
121.27M
est: 90.28M (+34.3%)
|
153.55M
est: 169.09M (-9.2%)
|
202.54M
est: 144.91M (+39.8%)
|
245.16M
est: 178.12M (+37.6%)
|
285.77M
est: 239.64M (+19.2%)
|
326.00M
est: 223.48M (+45.9%)
|
332.54M
est: 346.72M (-4.1%)
|
300.91M
est: 309.46M (-2.8%)
|
347.14M
est: 711.48M (-51.2%)
|
426.36M
343.24M – 471.46M
-40.1% YoY
|
485.94M
403.07M – 602.72M
+14.0% YoY
|
571.88M
563.99M – 579.78M
+17.7% YoY
|
646.79M
491.67M – 768.71M
+13.1% YoY
|
702.54M
534.05M – 834.96M
+8.6% YoY
|
| EPS |
-2.97
est: -2.63 (-12.9%)
|
-5.07
est: -4.70 (-7.9%)
|
-4.17
est: -4.40 (+5.2%)
|
-2.02
est: -2.14 (+5.8%)
|
-2.75
est: -2.10 (-31.2%)
|
-4.27
est: -3.14 (-36.2%)
|
-6.64
est: -6.32 (-5.1%)
|
-7.43
est: -6.68 (-11.2%)
|
-7.79
est: -6.96 (-11.9%)
|
-8.37
est: -6.31 (-32.7%)
|
-4.73
est: -4.45 (-6.2%)
|
8.58
est: 9.50 (-9.7%)
|
0.06
-0.03 – 0.24
-99.4% YoY
|
1.86
-1.77 – 3.57
+2,928.0% YoY
|
1.91
-0.75 – 4.46
+2.7% YoY
|
3.75
2.58 – 4.67
+96.3% YoY
|
4.80
3.30 – 5.97
+27.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-15 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-384.91M
OE per share TTM
-4.68
Owner's Yield
-7.23%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
16.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
87
Total invested
265.17M
Insider transactions (90d)
1
Beneficial owners (>5%)
39
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 6.86M | 9.10% | — | 6.86M | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 2 | Steven Boyd | 6.86M | 9.10% | — | 6.86M | — | — | HC, IN | United States of America | 2024-02-14 | ↗ |
| 3 | Wellington Group Holdings LLP | 6.82M | 10.85% | — | 6.21M | — | — | HC | Massachusetts | 2020-05-08 | ↗ |
| 4 | Wellington Investment Advisors Holdings LLP | 6.82M | 10.85% | — | 6.21M | — | — | HC | Massachusetts | 2020-05-08 | ↗ |
| 5 | Wellington Management Group LLP | 6.82M | 10.85% | — | 6.21M | — | — | HC | Massachusetts | 2020-05-08 | ↗ |
| 6 | Abigail P. Johnson | 6.72M | 10.54% | — | — | 6.72M | — | IN | Delaware | 2020-07-10 | ↗ |
| 7 | FMR LLC | 6.72M | 10.54% | 1.59M | — | 6.72M | — | HC | Delaware | 2020-07-10 | ↗ |
| 8 | Wellington Management Company LLP | 6.70M | 10.66% | — | 6.18M | — | — | IA | Massachusetts | 2020-05-08 | ↗ |
| 9 | Complete Pharma Holdings II, LLC | 6.68M | 16.20% | 6.68M | — | 6.68M | — | OO | Delaware | 2017-04-27 | ↗ |
| 10 | Jeremy Mindich | 4.14M | 9.90% | — | 4.14M | — | 4.14M | HC, IN | Delaware | 2018-02-14 | ↗ |
| 11 | Matthew Sirovich | 4.14M | 9.90% | — | 4.14M | — | 4.14M | HC, IN | Delaware | 2018-02-14 | ↗ |
| 12 | Scopia Capital Management LP | 4.14M | 9.90% | — | 4.14M | — | 4.14M | IA, PN | Delaware | 2018-02-14 | ↗ |
| 13 | Scopia Management, Inc. | 4.14M | 9.90% | — | 4.14M | — | 4.14M | HC, CO | Delaware | 2018-02-14 | ↗ |
| 14 | Roderick Wong | 4.13M | 9.95% | — | 4.13M | — | 4.13M | HC, IN | OR PLACE OF ORGANIZATION | 2018-02-14 | ↗ |
| 15 | Capital Appreciation Fund. | 4.08M | 5.99% | — | 4.08M | — | — | IV | Maryland | 2021-02-09 | ↗ |
| 16 | RTW Master Fund, Ltd. | 3.93M | 9.47% | — | 3.93M | — | 3.93M | CO | OR PLACE OF ORGANIZATION | 2018-02-14 | ↗ |
| 17 | Janus Henderson Group plc | 3.90M | 5.50% | — | 3.90M | — | 3.90M | IA, HC | Jersey, Channel Islands | 2022-02-11 | ↗ |
| 18 | RTW Investments, LP | 3.83M | 6.22% | — | 3.83M | — | 3.83M | IA, PN, OO | Delaware, United States of America | 2020-02-14 | ↗ |
| 19 | Steven A. Cohen | 2.93M | 4.00% | — | 2.93M | — | 2.93M | IN | Delaware | 2019-05-21 | ↗ |
| 20 | Point72 Asset Management, L.P. | 2.89M | 4.00% | — | 2.89M | — | 2.89M | PN | Delaware | 2019-05-21 | ↗ |
| 21 | Point72 Capital Advisors, Inc. | 2.89M | 4.00% | — | 2.89M | — | 2.89M | CO | Delaware | 2019-05-21 | ↗ |
| 22 | 52-0556948 | 2.75M | 5.40% | 349.6K | — | 2.75M | — | IA | Maryland | 2019-02-14 | ↗ |
| 23 | 10 | 2.50M | 6.00% | — | 2.50M | — | 2.50M | OO | Delaware | 2018-01-26 | ↗ |
| 24 | STATE STREET CORPORATION | 2.40M | 4.80% | — | 2.26M | — | 2.40M | HC | BOSTON, MASSACHUSETTS | 2019-02-13 | ↗ |
| 25 | 13-3695715 | 2.33M | 5.00% | — | 2.26M | — | — | IA, PN | Delaware | 2018-05-29 | ↗ |
| 26 | David E. Shaw | 2.33M | 5.00% | — | 2.26M | — | — | IN | Delaware | 2018-05-29 | ↗ |
| 27 | Dr. Jeffrey R. Jay, M.D. | 2.16M | 5.24% | — | 2.16M | — | 2.16M | IN | USA | 2017-06-16 | ↗ |
| 28 | Great Point Partners, LLC | 2.16M | 5.24% | — | 2.16M | — | 2.16M | IA | USA | 2017-06-16 | ↗ |
| 29 | Mr. David Kroin | 2.16M | 5.24% | — | 2.16M | — | 2.16M | IN | USA | 2017-06-16 | ↗ |
| 30 | (1) BlackRock, Inc. | 1.90M | 5.60% | 1.84M | — | 1.90M | — | HC | Delaware | 2015-02-03 | ↗ |
| 31 | of 12 Pages | 1.70M | 6.80% | 1.70M | — | 1.70M | — | IN | U.S. | 2014-02-14 | ↗ |
| 32 | 04-2683227 | 1.47M | 5.90% | — | 1.38M | — | — | IA | Massachusetts | 2014-02-14 | ↗ |
| 33 | PTC Therapeutics, Inc. | 1.29M | 9.56% | 1.29M | — | 1.29M | 10.00 | CO | Delaware | 2019-05-24 | ↗ |
| 34 | Cubist Systematic Strategies, LLC | 41.4K | 4.00% | — | 41.4K | — | 41.4K | OO | Delaware | 2019-05-21 | ↗ |
| 35 | Camber Capital Management LP | 2.0K | 5.31% | — | 4.00M | — | 4.00M | OO | Delaware | 2023-10-30 | ↗ |
| 36 | Point72 Hong Kong Limited | 590.00 | 4.00% | — | 590.00 | — | 590.00 | OO | Delaware | 2019-05-21 | ↗ |
| 37 | Appreciation Fund. | — | 0.00% | — | — | — | — | IV | Maryland | 2022-02-11 | ↗ |
| 38 | SAMUEL R. SHAPIRO | — | 0.00% | — | 2.00M | — | 2.00M | IN | Massachusetts | 2016-09-29 | ↗ |
| 39 | Westfield Capital Management Company, LP | — | 0.00% | — | — | — | — | IA | Massachusetts | 2017-02-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
87
-274 vs prev Q
New positions
8
Closed positions
270
Increased
45
Reduced
29
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 12.78M +5.6M (+79.2%) | 970.70M +533.1M (+121.8%) | 15.68% +6.556 pp | 0.02% +0.009 pp | USD54.28 +39.9% | 6 qtrs — |
| 2 | VANGUARD GROUP INC | 8.80M +514.2K (+6.2%) | 668.69M +160.0M (+31.5%) | 10.80% +0.196 pp | 0.01% +0.002 pp | USD39.39 +92.8% | 50 qtrs — |
| 3 | RTW INVESTMENTS, LP | 7.75M +— (+0.0%) | 588.42M +113.0M (+23.8%) | 9.51% -0.407 pp | 5.89% +0.037 pp | USD38.51 +97.2% | 37 qtrs — |
| 4 | JANUS HENDERSON GROUP PLC | 4.85M +1.1M (+28.6%) | 368.59M +136.9M (+59.1%) | 5.95% +1.124 pp | 0.17% +0.059 pp | USD53.35 +42.4% | 28 qtrs — |
| 5 | STATE STREET CORP | 4.21M +1.1M (+34.2%) | 319.50M +127.1M (+66.1%) | 5.16% +1.150 pp | 0.01% +0.004 pp | USD45.97 +65.2% | 50 qtrs — |
| 6 | TORONTO DOMINION BANK | 4.14M +891.7K (+27.5%) | 314.34M +115.1M (+57.8%) | 5.08% +0.924 pp | 0.46% +0.155 pp | USD54.92 +38.3% | 5 qtrs — |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 3.87M -1.1M (-21.4%) | 293.77M -8.1M (-2.7%) | 4.75% -1.548 pp | 0.05% -0.001 pp | USD40.60 +87.1% | 50 qtrs — |
| 8 | ARMISTICE CAPITAL, LLC | 2.80M -475.4K (-14.5%) | 212.83M +11.7M (+5.8%) | 3.44% -0.756 pp | 2.53% -0.451 pp | USD31.13 +144.0% | 29 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.02M +65.2K (+3.3%) | 153.16M +33.4M (+27.9%) | 2.47% -0.023 pp | 0.01% +0.002 pp | USD39.10 +94.3% | 50 qtrs — |
| 10 | D. E. SHAW & CO., INC. | 1.74M -429.6K (-19.8%) | 132.55M -906.2K (-0.7%) | 2.14% -0.641 pp | 0.07% -0.003 pp | USD38.47 +97.5% | 42 qtrs — |
| 11 | FMR LLC | 1.68M +69.4K (+4.3%) | 127.71M +28.8M (+29.1%) | 2.06% +0.001 pp | 0.01% +0.001 pp | USD49.21 +54.4% | 50 qtrs — |
| 12 | JEFFERIES FINANCIAL GROUP INC. | 1.66M +73.8K (+4.7%) | 125.98M +28.7M (+29.5%) | 2.04% +0.007 pp | 0.64% +0.185 pp | USD62.02 +22.5% | 2 qtrs — |
| 13 | TANG CAPITAL MANAGEMENT LLC | 1.50M +— (+0.0%) | 113.94M +21.9M (+23.8%) | 1.84% -0.079 pp | 5.63% +2.085 pp | USD42.67 +78.0% | 9 qtrs — |
| 14 | BANK OF AMERICA CORP /DE/ | 1.43M -85.5K (-5.6%) | 108.74M +15.6M (+16.8%) | 1.76% -0.185 pp | 0.01% +0.002 pp | USD48.35 +57.1% | 49 qtrs — |
| 15 | FRANKLIN RESOURCES INC | 1.29M +129.7K (+11.2%) | 97.74M +26.7M (+37.6%) | 1.58% +0.098 pp | 0.02% +0.006 pp | USD44.62 +70.2% | 30 qtrs — |
| 16 | CITADEL ADVISORS LLC | 1.15M -576.6K (-33.3%) | 87.69M -18.5M (-17.5%) | 1.42% -0.798 pp | 0.01% -0.003 pp | USD53.09 +43.1% | 48 qtrs — |
| 17 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1.14M +4.4K (+0.4%) | 86.30M +16.8M (+24.3%) | 1.39% -0.054 pp | 0.59% +0.089 pp | USD47.99 +58.3% | 5 qtrs — |
| 18 | POINT72 ASSET MANAGEMENT, L.P. | 1.13M -92.1K (-7.5%) | 85.72M +10.8M (+14.4%) | 1.38% -0.177 pp | 0.10% -0.030 pp | USD61.37 +23.8% | 9 qtrs — |
| 19 | GOLDMAN SACHS GROUP INC | 1.02M +146.7K (+16.7%) | 77.71M +23.9M (+44.5%) | 1.26% +0.134 pp | 0.01% +0.003 pp | USD45.58 +66.7% | 46 qtrs — |
| 20 | HOOD RIVER CAPITAL MANAGEMENT LLC | 1.00M +7.3K (+0.7%) | 76.19M +15.1M (+24.7%) | 1.23% -0.043 pp | 0.84% +0.114 pp | USD53.70 +41.5% | 4 qtrs — |
| 21 | PICTET ASSET MANAGEMENT HOLDING SA | 979.0K -429.0K (-30.5%) | 74.79M -11.4M (-13.3%) | 1.20% -0.600 pp | 0.07% -0.011 pp | USD45.00 +68.8% | 10 qtrs — |
| 22 | UBS GROUP AG | 964.7K +512.4K (+113.3%) | 73.28M +45.5M (+164.0%) | 1.18% +0.605 pp | 0.01% +0.008 pp | USD61.12 +24.3% | 45 qtrs — |
| 23 | MORGAN STANLEY | 905.2K +485.8K (+115.8%) | 68.76M +43.0M (+167.1%) | 1.11% +0.574 pp | 0.00% +0.003 pp | USD56.31 +34.9% | 49 qtrs — |
| 24 | PALO ALTO INVESTORS LP | 903.9K +41.3K (+4.8%) | 68.66M +15.7M (+29.7%) | 1.11% +0.005 pp | 9.56% -0.238 pp | USD52.51 +44.7% | 6 qtrs — |
| 25 | SG AMERICAS SECURITIES, LLC | 894.5K +764.4K (+587.5%) | 67.94M +60.0M (+751.0%) | 1.10% +0.931 pp | 0.09% +0.060 pp | USD73.78 +3.0% | 6 qtrs — |
| 26 | BNP PARIBAS ARBITRAGE, SNC | 828.7K +808.5K (+4,013.1%) | 62.95M +61.7M (+4,990.9%) | 1.02% +0.991 pp | 0.03% +0.028 pp | USD75.28 +0.9% | 49 qtrs — |
| 27 | NORTHERN TRUST CORP | 769.4K +31.9K (+4.3%) | 58.45M +13.2M (+29.1%) | 0.94% +0.000 pp | 0.01% +0.002 pp | USD34.46 +120.4% | 50 qtrs — |
| 28 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 734.9K +32.2K (+4.6%) | 55.83M +12.7M (+29.4%) | 0.90% +0.003 pp | 0.01% +0.002 pp | USD36.96 +105.5% | 50 qtrs — |
| 29 | NUVEEN, LLC | 699.2K -22.0K (-3.1%) | 53.11M +8.9M (+20.0%) | 0.86% -0.065 pp | 0.01% +0.002 pp | USD50.96 +49.1% | 4 qtrs — |
| 30 | AVORO CAPITAL ADVISORS LLC | 685.0K +685.0K (+100.0%) | 52.03M +52.0M (+100.0%) | 0.84% +0.841 pp | 0.50% +0.500 pp | USD75.96 +0.0% | 1 qtrs NEW |
| 31 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 647.6K -153.3K (-19.1%) | 49.19M +41.0K (+0.1%) | 0.79% -0.230 pp | 0.06% -0.071 pp | USD43.34 +75.3% | 30 qtrs — |
| 32 | LORD, ABBETT & CO. LLC | 627.1K +249.1K (+65.9%) | 47.64M +24.4M (+105.3%) | 0.77% +0.286 pp | 0.15% +0.077 pp | USD59.61 +27.4% | 3 qtrs — |
| 33 | DIMENSIONAL FUND ADVISORS LP | 627.1K -146.1K (-18.9%) | 47.63M +185.6K (+0.4%) | 0.77% -0.220 pp | 0.01% 0.000 pp | USD53.53 +41.9% | 5 qtrs — |
| 34 | RENAISSANCE TECHNOLOGIES LLC | 607.6K -319.7K (-34.5%) | 46.15M -10.8M (-18.9%) | 0.75% -0.441 pp | 0.07% -0.004 pp | USD35.96 +111.2% | 10 qtrs — |
| 35 | WOODLINE PARTNERS LP | 571.6K +465.9K (+441.2%) | 43.42M +36.9M (+569.9%) | 0.70% +0.566 pp | 0.17% +0.138 pp | USD73.26 +3.7% | 2 qtrs — |
| 36 | BANK OF NEW YORK MELLON CORP | 514.7K +241.6K (+88.5%) | 39.10M +22.3M (+133.3%) | 0.63% +0.282 pp | 0.01% +0.004 pp | USD58.38 +30.1% | 50 qtrs — |
| 37 | BOSTON PARTNERS | 488.0K +126.3K (+34.9%) | 37.07M +14.9M (+67.0%) | 0.60% +0.136 pp | 0.04% +0.016 pp | USD65.15 +16.6% | 2 qtrs — |
| 38 | PRINCIPAL FINANCIAL GROUP INC | 478.9K +411.2K (+607.6%) | 36.38M +32.2M (+775.9%) | 0.59% +0.501 pp | 0.02% +0.017 pp | USD72.37 +5.0% | 33 qtrs — |
| 39 | PRICE T ROWE ASSOCIATES INC /MD/ | 460.1K +1.8K (+0.4%) | 34.95M +6.8M (+24.3%) | 0.56% -0.022 pp | 0.00% +0.001 pp | USD44.37 +71.2% | 31 qtrs — |
| 40 | INVESCO LTD. | 434.3K +121.2K (+38.7%) | 32.99M +13.8M (+71.7%) | 0.53% +0.132 pp | 0.01% +0.002 pp | USD55.32 +37.3% | 37 qtrs — |
| 41 | BIOIMPACT CAPITAL LLC | 430.0K -8.5K (-1.9%) | 32.66M +5.8M (+21.4%) | 0.53% -0.033 pp | 3.74% -0.668 pp | USD43.57 +74.3% | 6 qtrs — |
| 42 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 426.5K +1.5K (+0.4%) | 32.40M +6.3M (+24.2%) | 0.52% -0.021 pp | 0.03% +0.005 pp | USD59.18 +28.4% | 50 qtrs — |
| 43 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 406.4K +82.9K (+25.6%) | 30.87M +11.0M (+55.5%) | 0.50% +0.085 pp | 0.02% +0.006 pp | USD63.30 +20.0% | 3 qtrs — |
| 44 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 405.5K -68.2K (-14.4%) | 30.80M +1.7M (+6.0%) | 0.50% -0.109 pp | 0.06% -0.001 pp | USD32.37 +134.7% | 19 qtrs — |
| 45 | LEGAL & GENERAL GROUP PLC | 366.3K +124.9K (+51.8%) | 27.82M +13.0M (+87.8%) | 0.45% +0.141 pp | 0.01% +0.003 pp | USD57.59 +31.9% | 46 qtrs — |
| 46 | JUPITER ASSET MANAGEMENT LTD | 361.2K +361.2K (+100.0%) | 27.43M +27.4M (+100.0%) | 0.44% +0.443 pp | 0.22% +0.220 pp | USD75.96 +0.0% | 3 qtrs — |
| 47 | PANAGORA ASSET MANAGEMENT INC | 359.8K +11.5K (+3.3%) | 27.33M +6.0M (+27.8%) | 0.44% -0.004 pp | 0.10% +0.011 pp | USD46.59 +63.0% | 32 qtrs — |
| 48 | JPMORGAN CHASE & CO | 356.0K -134.9K (-27.5%) | 27.04M -3.1M (-10.2%) | 0.44% -0.191 pp | 0.00% 0.000 pp | USD42.42 +79.1% | 33 qtrs — |
| 49 | AQR CAPITAL MANAGEMENT LLC | 341.9K +10.7K (+3.2%) | 25.97M +5.6M (+27.8%) | 0.42% -0.004 pp | 0.01% +0.001 pp | USD46.78 +62.4% | 17 qtrs — |
| 50 | VOYA INVESTMENT MANAGEMENT LLC | 339.1K +54.3K (+19.0%) | 25.76M +8.3M (+47.3%) | 0.42% +0.052 pp | 0.03% +0.008 pp | USD51.78 +46.7% | 47 qtrs — |
| 51 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 324.6K +324.6K (+100.0%) | 24.66M +24.7M (+100.0%) | 0.40% +0.398 pp | 0.08% +0.083 pp | USD75.96 +0.0% | 1 qtrs NEW |
| 52 | ENSIGN PEAK ADVISORS, INC | 280.6K -8.2K (-2.8%) | 21.31M +3.6M (+20.3%) | 0.34% -0.025 pp | 0.04% +0.009 pp | USD38.46 +97.5% | 25 qtrs — |
| 53 | RUSSELL INVESTMENTS GROUP, LTD. | 270.7K +23.3K (+9.4%) | 20.57M +5.4M (+35.4%) | 0.33% +0.016 pp | 0.02% +0.005 pp | USD55.80 +36.1% | 37 qtrs — |
| 54 | EMPOWERED FUNDS, LLC | 250.4K +206.7K (+473.0%) | 19.02M +16.3M (+609.2%) | 0.31% +0.251 pp | 0.15% +0.124 pp | USD71.62 +6.1% | 4 qtrs — |
| 55 | MARSHALL WACE, LLP | 247.7K +90.0K (+57.1%) | 18.82M +9.1M (+94.4%) | 0.30% +0.102 pp | 0.02% +0.007 pp | USD60.04 +26.5% | 4 qtrs — |
| 56 | MACKENZIE FINANCIAL CORP | 236.9K +35.1K (+17.4%) | 18.01M +5.6M (+45.5%) | 0.29% +0.033 pp | 0.02% +0.006 pp | USD61.25 +24.0% | 7 qtrs — |
| 57 | PACER ADVISORS, INC. | 235.7K -268.3K (-53.2%) | 17.90M -13.0M (-42.1%) | 0.29% -0.356 pp | 0.05% -0.032 pp | USD48.84 +55.5% | 3 qtrs — |
| 58 | DEUTSCHE BANK AG\ | 231.3K +151.4K (+189.5%) | 17.57M +12.7M (+258.3%) | 0.28% +0.182 pp | 0.01% +0.004 pp | USD66.48 +14.3% | 50 qtrs — |
| 59 | DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN | 220.8K -16.3K (-6.9%) | 16.78M +2.2M (+15.3%) | 0.27% -0.032 pp | 0.01% +0.002 pp | USD50.38 +50.8% | 3 qtrs — |
| 60 | BARCLAYS PLC | 220.2K +53.2K (+31.8%) | 16.73M +10.5M (+169.9%) | 0.27% +0.057 pp | 0.00% +0.002 pp | USD50.92 +49.2% | 50 qtrs — |
| 61 | RHUMBLINE ADVISERS | 208.0K +94.0K (+82.6%) | 15.80M +8.8M (+126.0%) | 0.26% +0.109 pp | 0.01% +0.007 pp | USD55.40 +37.1% | 47 qtrs — |
| 62 | BOXER CAPITAL MANAGEMENT, LLC | 200.0K +— (+0.0%) | 15.19M +2.9M (+23.8%) | 0.25% -0.011 pp | 3.33% -0.587 pp | USD61.37 +23.8% | 2 qtrs — |
| 63 | PRUDENTIAL FINANCIAL INC | 183.2K +95.7K (+109.5%) | 13.91M +8.5M (+159.3%) | 0.22% +0.113 pp | 0.02% +0.010 pp | USD63.53 +19.6% | 6 qtrs — |
| 64 | PARKMAN HEALTHCARE PARTNERS LLC | 160.2K -42.2K (-20.8%) | 12.17M -251.8K (-2.0%) | 0.20% -0.062 pp | 1.16% -0.137 pp | USD44.15 +72.0% | 6 qtrs — |
| 65 | BI ASSET MANAGEMENT FONDSMAEGLERSELSKAB A/S | 159.5K +64.5K (+67.9%) | 12.11M +6.3M (+107.8%) | 0.20% +0.074 pp | 0.11% +0.054 pp | USD59.82 +27.0% | 4 qtrs — |
| 66 | FIRST TRUST ADVISORS LP | 155.6K +33.7K (+27.7%) | 11.82M +4.3M (+58.0%) | 0.19% +0.035 pp | 0.01% +0.003 pp | USD43.59 +74.3% | 17 qtrs — |
| 67 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 151.4K +19.3K (+14.6%) | 11.50M +3.4M (+41.9%) | 0.19% +0.017 pp | 0.02% +0.005 pp | USD51.10 +48.6% | 5 qtrs — |
| 68 | AMERIPRISE FINANCIAL INC | 147.6K +137.0K (+1,288.4%) | 11.21M +10.6M (+1,618.4%) | 0.18% +0.168 pp | 0.00% +0.002 pp | USD72.93 +4.2% | 16 qtrs — |
| 69 | SWISS NATIONAL BANK | 141.1K +2.8K (+2.0%) | 10.72M +2.2M (+26.3%) | 0.17% -0.004 pp | 0.01% +0.002 pp | USD37.97 +100.1% | 49 qtrs — |
| 70 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 141.0K -150.0K (-51.5%) | 10.71M -7.1M (-40.0%) | 0.17% -0.199 pp | 0.02% -0.012 pp | USD41.87 +81.4% | 16 qtrs — |
| 71 | UBS ASSET MANAGEMENT AMERICAS INC | 131.9K +2.0K (+1.5%) | 10.02M +2.0M (+25.7%) | 0.16% -0.004 pp | 0.00% +0.000 pp | USD41.39 +83.5% | 46 qtrs — |
| 72 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 129.2K -90.5K (-41.2%) | 9.81M -3.7M (-27.2%) | 0.16% -0.123 pp | 0.00% 0.000 pp | USD49.32 +54.0% | 45 qtrs — |
| 73 | IKARIAN CAPITAL, LLC | 118.7K -161.9K (-57.7%) | 9.01M -8.2M (-47.7%) | 0.15% -0.213 pp | 0.70% -1.035 pp | USD61.37 +23.8% | 2 qtrs — |
| 74 | FEDERATED HERMES, INC. | 112.6K +97.8K (+659.8%) | 8.55M +7.6M (+840.4%) | 0.14% +0.119 pp | 0.01% +0.013 pp | USD72.18 +5.2% | 5 qtrs — |
| 75 | NEUBERGER BERMAN GROUP LLC | 111.6K +108.0K (+2,993.7%) | 8.48M +8.3M (+3,729.2%) | 0.14% +0.132 pp | 0.01% +0.006 pp | USD75.49 +0.6% | 2 qtrs — |
| 76 | WCM INVESTMENT MANAGEMENT, LLC | 110.3K -36.8K (-25.0%) | 8.40M -518.2K (-5.8%) | 0.14% -0.053 pp | 0.02% -0.001 pp | USD61.37 +23.8% | 2 qtrs — |
| 77 | CAPTION MANAGEMENT, LLC | 100.0K +40.0K (+66.7%) | 7.60M +3.9M (+106.3%) | 0.12% +0.046 pp | 0.05% +0.023 pp | USD63.45 +19.7% | 3 qtrs — |
| 78 | CASTLEARK MANAGEMENT LLC | 96.9K +96.9K (+100.0%) | 7.36M +7.4M (+100.0%) | 0.12% +0.119 pp | 0.22% +0.216 pp | USD75.96 +0.0% | 1 qtrs NEW |
| 79 | ALLIANCEBERNSTEIN L.P. | 94.3K +2.3K (+2.5%) | 7.16M +1.5M (+26.9%) | 0.12% -0.002 pp | 0.00% +0.001 pp | USD39.89 +90.4% | 50 qtrs — |
| 80 | SEI INVESTMENTS CO | 92.1K +33.7K (+57.8%) | 6.99M +3.4M (+95.4%) | 0.11% +0.038 pp | 0.01% +0.003 pp | USD58.72 +29.4% | 5 qtrs — |
| 81 | WELLS FARGO & COMPANY/MN | 86.9K +35.5K (+69.0%) | 6.60M +3.4M (+109.1%) | 0.11% +0.041 pp | 0.00% +0.001 pp | USD58.68 +29.4% | 50 qtrs — |
| 82 | RAYMOND JAMES FINANCIAL INC | 86.0K +2.9K (+3.5%) | 6.53M +1.4M (+28.1%) | 0.11% -0.001 pp | 0.00% +0.000 pp | USD47.89 +58.6% | 5 qtrs — |
| 83 | PINNACLE ASSOCIATES LTD | 83.4K -5.2K (-5.8%) | 6.34M +900.5K (+16.6%) | 0.10% -0.011 pp | 0.08% +0.009 pp | USD33.41 +127.4% | 42 qtrs — |
| 84 | ROYCE & ASSOCIATES LP | 80.8K +48.0K (+146.5%) | 6.14M +4.1M (+205.1%) | 0.10% +0.057 pp | 0.06% +0.042 pp | USD64.96 +16.9% | 3 qtrs — |
| 85 | RAFFERTY ASSET MANAGEMENT, LLC | 78.5K -22.5K (-22.3%) | 5.96M -235.0K (-3.8%) | 0.10% -0.033 pp | 0.02% +0.001 pp | USD41.36 +83.7% | 28 qtrs — |
| 86 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 78.2K +44.2K (+130.0%) | 5.94M +3.9M (+188.2%) | 0.10% +0.052 pp | 0.01% +0.007 pp | USD63.48 +19.7% | 45 qtrs — |
| 87 | FCF ADVISORS LLC | 75.8K +75.8K (+100.0%) | 5.75M +5.8M (+100.0%) | 0.09% +0.093 pp | 0.75% +0.752 pp | USD75.96 +0.0% | 1 qtrs NEW |
| 88 | HILLSDALE INVESTMENT MANAGEMENT INC. | 75.7K -15.4K (-16.9%) | 5.75M +157.6K (+2.8%) | 0.09% -0.024 pp | 0.16% -0.010 pp | USD50.15 +51.5% | 7 qtrs — |
| 89 | CANADA PENSION PLAN INVESTMENT BOARD | 75.4K +75.4K (+100.0%) | 5.73M +5.7M (+100.0%) | 0.09% +0.093 pp | 0.00% +0.004 pp | USD75.96 +0.0% | 5 qtrs — |
| 90 | SCHRODER INVESTMENT MANAGEMENT GROUP | 72.6K +38.5K (+112.8%) | 5.53M +3.5M (+167.3%) | 0.09% +0.045 pp | 0.00% +0.003 pp | USD69.10 +9.9% | 2 qtrs — |
| 91 | ALYESKA INVESTMENT GROUP, L.P. | 72.3K +72.3K (+100.0%) | 5.49M +5.5M (+100.0%) | 0.09% +0.089 pp | 0.02% +0.016 pp | USD75.96 +0.0% | 3 qtrs — |
| 92 | EAM INVESTORS, LLC | 71.7K +71.7K (+100.0%) | 5.45M +5.4M (+100.0%) | 0.09% +0.088 pp | 0.61% +0.607 pp | USD75.96 +0.0% | 1 qtrs NEW |
| 93 | ACADIAN ASSET MANAGEMENT LLC | 69.5K +45.4K (+187.8%) | 5.27M +3.8M (+256.4%) | 0.09% +0.054 pp | 0.01% +0.006 pp | USD65.79 +15.5% | 7 qtrs — |
| 94 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 68.3K +3.8K (+5.8%) | 5.19M +1.2M (+31.0%) | 0.08% +0.001 pp | 0.01% +0.001 pp | USD35.54 +113.7% | 50 qtrs — |
| 95 | HRT FINANCIAL LP | 67.1K +55.3K (+469.2%) | 5.09M +4.4M (+604.6%) | 0.08% +0.067 pp | 0.02% +0.013 pp | USD73.40 +3.5% | 2 qtrs — |
| 96 | SECTOR GAMMA AS | 61.9K -56.2K (-47.6%) | 4.70M -2.5M (-35.1%) | 0.08% -0.075 pp | 1.07% -0.725 pp | USD50.02 +51.9% | 5 qtrs — |
| 97 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 61.9K +61.9K (+100.0%) | 4.70M +4.7M (+100.0%) | 0.08% +0.076 pp | 0.24% +0.241 pp | USD75.96 +0.0% | 1 qtrs NEW |
| 98 | VICTORY CAPITAL MANAGEMENT INC | 56.6K -19.5K (-25.7%) | 4.30M -373.9K (-8.0%) | 0.07% -0.028 pp | 0.00% 0.000 pp | USD46.91 +61.9% | 26 qtrs — |
| 99 | THRIVENT FINANCIAL FOR LUTHERANS | 55.2K +55.2K (+100.0%) | 4.19M +4.2M (+100.0%) | 0.07% +0.068 pp | 0.01% +0.007 pp | USD75.96 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 180 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco S&P SmallCap Health Care ETF PSCH | 3.07% | 5.03M | 0.29% |
| 2 | Invesco Biotechnology & Genome ETF PBE | 3.06% | 8.75M | 0.58% |
| 3 | Invesco S&P SmallCap Momentum ETF XSMO | 1.65% | 50.53M | 0.36% |
| 4 | Franklin Genomic Advancements ETF HELX | 1.51% | 455.3K | 0.50% |
| 5 | Cambria Value and Momentum ETF VAMO | 1.51% | 1.60M | 0.65% |
| 6 | Virtus Biotech ETF BBP | 1.46% | 1.43M | 0.34% |
| 7 | Invesco S&P SmallCap 600 Revenue ETF RZG | 1.45% | 2.08M | 0.35% |
| 8 | ETC 6 Meridian Small Cap Equity ETF SIXS | 1.45% | 1.54M | 0.52% |
| 9 | First Trust Nasdaq Pharmaceuticals ETF FTXH | 1.42% | 516.7K | 0.60% |
| 10 | Harbor Health Care ETF (MEDI) MEDI | 1.33% | 578.4K | 0.80% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.13
Bearish
Ratio by volume
0.04
Bearish
Buys
1
Sells
8
Shares acquired
2.3K
Shares disposed
60.2K
Cash buys
—
Cash sales
7.00
Net activity
-57,947
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-21 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 2,850 | 70.91 | 202.1K | 394,070 | D | ↗ |
| 2026-04-06 | Boulding Mark Elliott | Officer | M-Exempt | A | Common Stock | 2,265 | 39.42 | 89.3K | 107,477 | D | ↗ |
| 2026-04-02 | Golden Lee Scott | Officer | S-Sale | D | Common Stock | 829 | 67.99 | 56.4K | 79,115 | D | ↗ |
| 2026-04-01 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 12,530 | 69.50 | 870.8K | 60,217 | D | ↗ |
| 2026-03-24 | Chutter Jessica Caroline | Director | A-Award | A | Common Stock | 3,333 | 0.00 | — | 7,333 | D | ↗ |
| 2026-03-12 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 2,662 | 64.08 | 170.6K | 396,920 | D | ↗ |
| 2026-03-11 | Klein Matthew B. | Director / Officer | A-Award | A | Common Stock | 12,500 | 0.00 | — | 399,582 | D | ↗ |
| 2026-03-10 | Okey Stephanie | Director | S-Sale | D | Common Stock | 14,000 | 70.00 | 980.0K | 8,000 | D | ↗ |
| 2026-03-05 | Okey Stephanie | Director | S-Sale | D | Common Stock | 6,333 | 63.38 | 401.4K | 8,000 | D | ↗ |
| 2026-03-05 | Golden Lee Scott | Officer | S-Sale | D | Common Stock | 10,000 | 63.38 | 633.8K | 79,944 | D | ↗ |
| 2026-03-05 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 3,989 | 63.38 | 252.8K | 2,737 | I | ↗ |
| 2026-02-19 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 590 | 69.82 | 41.2K | 105,212 | D | ↗ |
| 2026-02-18 | Utter Christine Marie | Officer | S-Sale | D | Common Stock | 2,494 | 69.36 | 173.0K | 70,199 | D | ↗ |
| 2026-02-18 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 3,019 | 69.36 | 209.4K | 77,122 | D | ↗ |
| 2026-02-18 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 7,371 | 69.36 | 511.3K | 387,082 | D | ↗ |
| 2026-02-18 | Gravier Pierre | Officer | S-Sale | D | Common Stock | 2,992 | 69.36 | 207.5K | 87,318 | D | ↗ |
| 2026-02-18 | Golden Lee Scott | Officer | S-Sale | D | Common Stock | 2,484 | 69.36 | 172.3K | 89,944 | D | ↗ |
| 2026-02-18 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 3,081 | 69.36 | 213.7K | 108,231 | D | ↗ |
| 2026-02-18 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 65 | 69.36 | 4.5K | 6,726 | I | ↗ |
| 2026-02-17 | Boulding Mark Elliott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,813 | 25.69 | 72.3K | 22,501 | D | ↗ |
| 2026-01-12 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 1,024 | 78.70 | 80.6K | 80,141 | D | ↗ |
| 2026-01-09 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 1,722 | 77.41 | 133.3K | 81,165 | D | ↗ |
| 2026-01-09 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 107 | 79.52 | 8.5K | 111,312 | D | ↗ |
| 2026-01-08 | Utter Christine Marie | Officer | S-Sale | D | Common Stock | 1,034 | 76.45 | 79.0K | 72,693 | D | ↗ |
| 2026-01-08 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 1,454 | 76.45 | 111.2K | 82,887 | D | ↗ |
| 2026-01-08 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 2,514 | 76.45 | 192.2K | 394,453 | D | ↗ |
| 2026-01-08 | Golden Lee Scott | Officer | S-Sale | D | Common Stock | 866 | 76.45 | 66.2K | 92,428 | D | ↗ |
| 2026-01-08 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 2,482 | 76.56 | 190.0K | 115,177 | D | ↗ |
| 2026-01-08 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 59 | 76.45 | 4.5K | 6,791 | I | ↗ |
| 2026-01-07 | Utter Christine Marie | Officer | S-Sale | D | Common Stock | 1,235 | 77.45 | 95.7K | 73,727 | D | ↗ |
| 2026-01-07 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 1,352 | 77.48 | 104.8K | 87,489 | D | ↗ |
| 2026-01-07 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 3,016 | 77.48 | 233.7K | 396,967 | D | ↗ |
| 2026-01-07 | Golden Lee Scott | Officer | S-Sale | D | Common Stock | 642 | 77.48 | 49.7K | 93,294 | D | ↗ |
| 2026-01-07 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 38 | 78.60 | 3.0K | 117,659 | D | ↗ |
| 2026-01-07 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 1,026 | 77.48 | 79.5K | 116,077 | D | ↗ |
| 2026-01-06 | Utter Christine Marie | Officer | S-Sale | D | Common Stock | 1,381 | 76.95 | 106.3K | 74,962 | D | ↗ |
| 2026-01-06 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 1,789 | 76.95 | 137.7K | 88,841 | D | ↗ |
| 2026-01-06 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 5,149 | 76.95 | 396.2K | 399,983 | D | ↗ |
| 2026-01-06 | Gravier Pierre | Officer | S-Sale | D | Common Stock | 2,139 | 76.95 | 164.6K | 90,310 | D | ↗ |
| 2026-01-06 | Golden Lee Scott | Officer | S-Sale | D | Common Stock | 1,340 | 76.95 | 103.1K | 93,936 | D | ↗ |
| 2026-01-06 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 1,739 | 76.95 | 133.8K | 119,162 | D | ↗ |
| 2026-01-06 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 1,279 | 76.95 | 98.4K | 117,103 | D | ↗ |
| 2026-01-05 | Reeve Emma | Director | M-Exempt | D | Stock Option (Right to Buy) | 734 | 46.54 | 34.2K | 0 | D | ↗ |
| 2026-01-05 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 1,123 | 74.92 | 84.1K | 122,044 | D | ↗ |
| 2026-01-02 | ZELDIS JEROME B | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 22,500 | D | ↗ |
| 2026-01-02 | Young Alethia | Director | A-Award | A | Stock Option (Right to Buy) | 3,475 | 76.74 | 266.7K | 3,475 | D | ↗ |
| 2026-01-02 | Utter Christine Marie | Officer | A-Award | A | Common Stock | 13,250 | 0.00 | — | 76,343 | D | ↗ |
| 2026-01-02 | Smith Mary L. | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 21,813 | D | ↗ |
| 2026-01-02 | STEELE GLENN JR MD PHD | Director | M-Exempt | A | Common Stock | 12,000 | 30.86 | 370.3K | 30,500 | D | ↗ |
| 2026-01-02 | SOUTHWELL DAVID P | Director | A-Award | A | Stock Option (Right to Buy) | 3,475 | 76.74 | 266.7K | 3,475 | D | ↗ |
| 2026-01-02 | SCHMERTZLER MICHAEL | Director | A-Award | A | Common Stock | 8,000 | 0.00 | — | 163,266 | D | ↗ |
| 2026-01-02 | Reeve Emma | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 10,666 | D | ↗ |
| 2026-01-02 | Pauwels Eric | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 90,630 | D | ↗ |
| 2026-01-02 | Okey Stephanie | Director | A-Award | A | Stock Option (Right to Buy) | 3,475 | 76.74 | 266.7K | 3,475 | D | ↗ |
| 2026-01-02 | Klein Matthew B. | Director / Officer | A-Award | A | Common Stock | 63,000 | 0.00 | — | 405,132 | D | ↗ |
| 2026-01-02 | Jacobson Allan Steven | Director | A-Award | A | Stock Option (Right to Buy) | 3,475 | 76.74 | 266.7K | 3,475 | D | ↗ |
| 2026-01-02 | Gravier Pierre | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 92,449 | D | ↗ |
| 2026-01-02 | Golden Lee Scott | Officer | A-Award | A | Common Stock | 18,750 | 0.00 | — | 95,276 | D | ↗ |
| 2026-01-02 | Boulding Mark Elliott | Officer | A-Award | A | Common Stock | 17,000 | 0.00 | — | 120,901 | D | ↗ |
| 2026-01-02 | Almstead Neil Gregory | Officer | A-Award | A | Common Stock | 17,500 | 0.00 | — | 118,382 | D | ↗ |
| 2025-12-30 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 8,089 | 76.64 | 619.9K | 341,875 | D | ↗ |
| 2025-12-19 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 59 | 78.01 | 4.6K | 70,373 | D | ↗ |
| 2025-12-18 | Pauwels Eric | Officer | M-Exempt | A | Common Stock | 251 | 18.01 | 4.5K | 70,624 | D | ↗ |
| 2025-12-17 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 1,245 | 75.28 | 93.7K | 72,912 | D | ↗ |
| 2025-12-16 | SCHMERTZLER MICHAEL | Director | M-Exempt | D | Stock Option (Right to Buy) | 24,000 | 30.86 | 740.6K | 0 | D | ↗ |
| 2025-12-03 | Reeve Emma | Director | S-Sale | D | Common Stock | 733 | 78.62 | 57.6K | 6,666 | D | ↗ |
| 2025-12-02 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 3,428 | 79.07 | 271.1K | 349,964 | D | ↗ |
| 2025-12-01 | Klein Matthew B. | Director / Officer | A-Award | A | Common Stock | 15,625 | 0.00 | — | 353,392 | D | ↗ |
| 2025-11-25 | Jacobson Allan Steven | Director | S-Sale | D | Common Stock | 700 | 85.32 | 59.7K | 17,451 | D | ↗ |
| 2025-11-25 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 200 | 85.37 | 17.1K | 100,625 | D | ↗ |
| 2025-11-24 | Jacobson Allan Steven | Director | M-Exempt | D | Stock Option (Right to Buy) | 6,100 | 18.01 | 109.9K | 7,900 | D | ↗ |
| 2025-11-24 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 4,715 | 80.15 | 377.9K | 100,625 | D | ↗ |
| 2025-11-21 | Reeve Emma | Director | M-Exempt | A | Common Stock | 10,000 | 51.16 | 511.6K | 16,666 | D | ↗ |
| 2025-11-20 | Okey Stephanie | Director | G-Gift | D | Common Stock | 867 | 0.00 | — | 8,000 | D | ↗ |
| 2025-11-17 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 777 | 76.53 | 59.5K | 104,093 | D | ↗ |
| 2025-11-12 | Reeve Emma | Director | M-Exempt | A | Common Stock | 7,333 | 46.54 | 341.3K | 13,999 | D | ↗ |
| 2025-10-30 | Reeve Emma | Director | M-Exempt | A | Common Stock | 12,000 | 38.10 | 457.2K | 18,666 | D | ↗ |
| 2025-10-07 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 1,306 | 63.80 | 83.3K | 104,213 | D | ↗ |
| 2025-10-06 | Boulding Mark Elliott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,266 | 39.42 | 89.3K | 11,329 | D | ↗ |
| 2025-10-03 | Reeve Emma | Director | M-Exempt | A | Common Stock | 10,000 | 39.42 | 394.2K | 20,332 | D | ↗ |
| 2025-10-03 | Jacobson Allan Steven | Director | M-Exempt | D | Stock Option (Right to Buy) | 12,000 | 30.86 | 370.3K | 0 | D | ↗ |
| 2025-10-03 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 824 | 65.73 | 54.2K | 104,807 | D | ↗ |
| 2025-10-03 | Almstead Neil Gregory | Officer | M-Exempt | A | Common Stock | 51,558 | 30.86 | 1.59M | 152,183 | D | ↗ |
| 2025-09-12 | Boulding Mark Elliott | Officer | M-Exempt | A | Common Stock | 1,019 | 38.10 | 38.8K | 104,920 | D | ↗ |
| 2025-09-11 | Reeve Emma | Director | M-Exempt | A | Common Stock | 10,000 | 25.69 | 256.9K | 20,332 | D | ↗ |
| 2025-09-11 | Boulding Mark Elliott | Officer | M-Exempt | A | Common Stock | 2,356 | 38.10 | 89.8K | 106,257 | D | ↗ |
| 2025-09-09 | SOUTHWELL DAVID P | Director | S-Sale | D | Common Stock | 12,000 | 58.34 | 700.1K | 16,850 | D | ↗ |
| 2025-09-08 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 1,250 | 56.86 | 71.1K | 72,912 | D | ↗ |
| 2025-08-28 | Jacobson Allan Steven | Director | S-Sale | D | Common Stock | 1,667 | 50.15 | 83.6K | 17,451 | D | ↗ |
| 2025-08-15 | Boulding Mark Elliott | Officer | M-Exempt | A | Common Stock | 2,813 | 25.69 | 72.3K | 106,714 | D | ↗ |
| 2025-08-05 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 10,739 | 51.74 | 555.6K | 337,767 | D | ↗ |
| 2025-08-01 | Klein Matthew B. | Director / Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 348,506 | D | ↗ |
| 2025-07-15 | Gravier Pierre | Officer | S-Sale | D | Common Stock | 2,516 | 49.46 | 124.4K | 71,920 | D | ↗ |
| 2025-05-16 | Boulding Mark Elliott | Officer | M-Exempt | A | Common Stock | 883 | 25.69 | 22.7K | 104,784 | D | ↗ |
| 2025-05-15 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 1,929 | 46.18 | 89.1K | 103,901 | D | ↗ |
| 2025-04-22 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 2,804 | 48.74 | 136.7K | 273,234 | D | ↗ |
| 2025-04-02 | Golden Lee Scott | Officer | S-Sale | D | Common Stock | 897 | 46.95 | 42.1K | 75,997 | D | ↗ |
| 2025-03-17 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 2,037 | 55.24 | 112.5K | 77,365 | D | ↗ |
| 2025-03-14 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 4,458 | 55.19 | 246.0K | 79,402 | D | ↗ |
| 2025-03-13 | Okey Stephanie | Director | S-Sale | D | Common Stock | 5,000 | 54.00 | 270.0K | 8,867 | D | ↗ |
| 2025-03-12 | Boulding Mark Elliott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,395 | 33.02 | 79.1K | 0 | D | ↗ |
| 2025-03-11 | Boulding Mark Elliott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,719 | 33.02 | 56.8K | 2,395 | D | ↗ |
| 2025-03-10 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 11,398 | 53.12 | 605.5K | 103,901 | D | ↗ |
| 2025-03-04 | Jacobson Allan Steven | Director | S-Sale | D | Common Stock | 1,230 | 51.52 | 63.4K | 19,118 | D | ↗ |
| 2025-02-20 | Utter Christine Marie | Officer | S-Sale | D | Common Stock | 878 | 50.12 | 44.0K | 62,564 | D | ↗ |
| 2025-02-20 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 1,567 | 50.12 | 78.5K | 83,860 | D | ↗ |
| 2025-02-20 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 3,895 | 50.12 | 195.2K | 276,038 | D | ↗ |
| 2025-02-20 | Gravier Pierre | Officer | S-Sale | D | Common Stock | 1,167 | 50.12 | 58.5K | 74,436 | D | ↗ |
| 2025-02-20 | Golden Lee Scott | Officer | S-Sale | D | Common Stock | 962 | 50.12 | 48.2K | 76,894 | D | ↗ |
| 2025-02-20 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 1,614 | 50.12 | 80.9K | 103,901 | D | ↗ |
| 2025-02-20 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 1,578 | 50.12 | 79.1K | 100,353 | D | ↗ |
| 2025-02-19 | Utter Christine Marie | Officer | S-Sale | D | Common Stock | 879 | 50.10 | 44.0K | 63,442 | D | ↗ |
| 2025-02-19 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 1,378 | 50.10 | 69.0K | 85,427 | D | ↗ |
| 2025-02-19 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 3,897 | 50.10 | 195.2K | 279,933 | D | ↗ |
| 2025-02-19 | Gravier Pierre | Officer | S-Sale | D | Common Stock | 1,168 | 50.10 | 58.5K | 75,603 | D | ↗ |
| 2025-02-19 | Golden Lee Scott | Officer | S-Sale | D | Common Stock | 795 | 50.10 | 39.8K | 77,856 | D | ↗ |
| 2025-02-19 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 1,333 | 50.10 | 66.8K | 105,515 | D | ↗ |
| 2025-02-19 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 1,300 | 50.10 | 65.1K | 101,931 | D | ↗ |
| 2025-01-08 | Utter Christine Marie | Officer | S-Sale | D | Common Stock | 1,662 | 44.50 | 74.0K | 64,321 | D | ↗ |
| 2025-01-08 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 2,136 | 44.50 | 95.1K | 86,805 | D | ↗ |
| 2025-01-08 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 2,402 | 44.50 | 106.9K | 283,830 | D | ↗ |
| 2025-01-08 | Golden Lee Scott | Officer | S-Sale | D | Common Stock | 1,198 | 44.50 | 53.3K | 78,651 | D | ↗ |
| 2025-01-08 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 1,998 | 44.50 | 88.9K | 106,848 | D | ↗ |
| 2025-01-08 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 107 | 44.50 | 4.8K | 5,975 | I | ↗ |
| 2025-01-07 | Utter Christine Marie | Officer | S-Sale | D | Common Stock | 1,291 | 45.34 | 58.5K | 65,983 | D | ↗ |
| 2025-01-07 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 1,599 | 45.34 | 72.5K | 88,941 | D | ↗ |
| 2025-01-07 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 2,142 | 45.34 | 97.1K | 286,232 | D | ↗ |
| 2025-01-07 | Golden Lee Scott | Officer | S-Sale | D | Common Stock | 810 | 45.34 | 36.7K | 79,849 | D | ↗ |
| 2025-01-07 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 1,543 | 45.34 | 70.0K | 108,846 | D | ↗ |
| 2025-01-07 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 1,265 | 45.34 | 57.4K | 104,783 | D | ↗ |
| 2025-01-03 | ZELDIS JEROME B | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 18,500 | D | ↗ |
| 2025-01-03 | Young Alethia | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 17,067 | D | ↗ |
| 2025-01-03 | Utter Christine Marie | Officer | A-Award | A | Common Stock | 14,000 | 0.00 | — | 67,274 | D | ↗ |
| 2025-01-03 | Smith Mary L. | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 17,813 | D | ↗ |
| 2025-01-03 | STEELE GLENN JR MD PHD | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 18,500 | D | ↗ |
| 2025-01-03 | SOUTHWELL DAVID P | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 16,850 | D | ↗ |
| 2025-01-03 | SCHMERTZLER MICHAEL | Director | A-Award | A | Common Stock | 8,000 | 0.00 | — | 131,266 | D | ↗ |
| 2025-01-03 | Reeve Emma | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 15,200 | D | ↗ |
| 2025-01-03 | Pauwels Eric | Officer | A-Award | A | Common Stock | 22,000 | 0.00 | — | 90,540 | D | ↗ |
| 2025-01-03 | Okey Stephanie | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 13,867 | D | ↗ |
| 2025-01-03 | Klein Matthew B. | Director / Officer | A-Award | A | Common Stock | 70,000 | 0.00 | — | 288,374 | D | ↗ |
| 2025-01-03 | Jacobson Allan Steven | Director | A-Award | A | Stock Option (Right to Buy) | 8,800 | 46.54 | 409.6K | 8,800 | D | ↗ |
| 2025-01-03 | Gravier Pierre | Officer | A-Award | A | Common Stock | 22,500 | 0.00 | — | 76,771 | D | ↗ |
| 2025-01-03 | Golden Lee Scott | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 46.54 | 2.33M | 50,000 | D | ↗ |
| 2025-01-03 | Boulding Mark Elliott | Officer | A-Award | A | Common Stock | 18,000 | 0.00 | — | 110,389 | D | ↗ |
| 2025-01-03 | Almstead Neil Gregory | Officer | A-Award | A | Common Stock | 715 | 0.00 | — | 6,137 | I | ↗ |
| 2024-12-31 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 8,279 | 45.16 | 373.9K | 217,528 | D | ↗ |
| 2024-12-03 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 1,405 | 54.05 | 75.9K | 92,389 | D | ↗ |
| 2024-12-02 | ZELDIS JEROME B | Director | S-Sale | D | Common Stock | 3,187 | 52.42 | 167.1K | 14,500 | D | ↗ |
| 2024-12-02 | Utter Christine Marie | Officer | M-Exempt | A | Common Stock | 3,105 | 51.00 | 158.4K | 55,533 | D | ↗ |
| 2024-12-02 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 1,960 | 52.17 | 102.3K | 92,389 | D | ↗ |
| 2024-12-02 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 277 | 52.76 | 14.6K | 4,576 | I | ↗ |
| 2024-07-16 | Gravier Pierre | Officer | S-Sale | D | Common Stock | 2,269 | 34.02 | 77.2K | 53,531 | — | ↗ |
| 2024-05-22 | ZELDIS JEROME B | Director | M-Exempt | A | Common Stock | 20,000 | 26.42 | 528.4K | 34,500 | — | ↗ |
| 2024-05-08 | SOUTHWELL DAVID P | Director | G-Gift | D | Common Stock | 1,650 | 0.00 | — | 12,850 | — | ↗ |
| 2024-05-07 | Golden Lee Scott | Officer | S-Sale | D | Common Stock | 175 | 32.82 | 5.7K | 59,813 | — | ↗ |
| 2024-04-19 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 3,361 | 24.89 | 83.7K | 225,807 | — | ↗ |
| 2024-04-17 | Pauwels Eric | Director / Officer | S-Sale | D | Common Stock | 787 | 25.14 | 19.8K | 67,694 | — | ↗ |
| 2024-04-17 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 1,307 | 25.14 | 32.9K | 229,168 | — | ↗ |
| 2024-04-02 | Golden Lee Scott | Officer | S-Sale | D | Common Stock | 526 | 28.37 | 14.9K | 59,988 | — | ↗ |
| 2024-02-15 | ZELDIS JEROME B | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 14,500 | — | ↗ |
| 2024-02-15 | Young Alethia | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 13,067 | — | ↗ |
| 2024-02-15 | Utter Christine Marie | Officer | A-Award | A | Common Stock | 2,900 | 0.00 | — | 52,428 | — | ↗ |
| 2024-02-15 | Smith Mary L. | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 13,813 | — | ↗ |
| 2024-02-15 | STEELE GLENN JR MD PHD | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 14,500 | — | ↗ |
| 2024-02-15 | SOUTHWELL DAVID P | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 14,500 | — | ↗ |
| 2024-02-15 | SCHMERTZLER MICHAEL | Director | A-Award | A | Common Stock | 8,000 | 0.00 | — | 123,266 | — | ↗ |
| 2024-02-15 | Reeve Emma | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 11,200 | — | ↗ |
| 2024-02-15 | Pauwels Eric | Officer | A-Award | A | Stock Option (Right to Buy) | 55,000 | 25.69 | 1.41M | 55,000 | — | ↗ |
| 2024-02-15 | Okey Stephanie | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 25.69 | 256.9K | 10,000 | — | ↗ |
| 2024-02-15 | Klein Matthew B. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 175,000 | 25.69 | 4.50M | 175,000 | — | ↗ |
| 2024-02-15 | Jacobson Allan Steven | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 16,348 | — | ↗ |
| 2024-02-15 | Gravier Pierre | Officer | A-Award | A | Stock Option (Right to Buy) | 47,500 | 25.69 | 1.22M | 47,500 | — | ↗ |
| 2024-02-15 | Golden Lee Scott | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 57,914 | — | ↗ |
| 2024-02-15 | Boulding Mark Elliott | Officer | A-Award | A | Common Stock | 18,000 | 0.00 | — | 89,189 | — | ↗ |
| 2024-02-15 | Bell William F. Jr. | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 10,333 | — | ↗ |
| 2024-02-15 | Almstead Neil Gregory | Officer | A-Award | A | Common Stock | 6,000 | 0.00 | — | 86,202 | — | ↗ |
| 2024-01-30 | Utter Christine Marie | Officer | S-Sale | D | Common Stock | 318 | 27.25 | 8.7K | 35,528 | — | ↗ |
| 2024-01-30 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 366 | 27.25 | 10.0K | 44,181 | — | ↗ |
| 2024-01-30 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 794 | 27.25 | 21.6K | 71,189 | — | ↗ |
| 2024-01-30 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 28 | 27.25 | 763.02 | 3,706 | — | ↗ |
| 2024-01-22 | Jacobson Allan Steven | Director | M-Exempt | A | Common Stock | 10,000 | 27.05 | 270.5K | 22,348 | — | ↗ |
| 2024-01-09 | Utter Christine Marie | Officer | S-Sale | D | Common Stock | 1,653 | 29.01 | 48.0K | 35,846 | — | ↗ |
| 2024-01-09 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 2,065 | 29.01 | 59.9K | 44,547 | — | ↗ |
| 2024-01-09 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 5,443 | 29.01 | 157.9K | 160,475 | — | ↗ |
| 2024-01-09 | Golden Lee Scott | Officer | S-Sale | D | Common Stock | 1,225 | 29.01 | 35.5K | 37,914 | — | ↗ |
| 2024-01-09 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 1,938 | 29.01 | 56.2K | 71,983 | — | ↗ |
| 2024-01-09 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 1,521 | 29.01 | 44.1K | 61,820 | — | ↗ |
| 2024-01-08 | Utter Christine Marie | Officer | S-Sale | D | Common Stock | 1,188 | 28.64 | 34.0K | 37,499 | — | ↗ |
| 2024-01-08 | SCHMERTZLER MICHAEL | Director | S-Sale | D | Common Stock | 1,500 | 27.81 | 41.7K | 115,266 | — | ↗ |
| 2024-01-08 | Pauwels Eric | Officer | S-Sale | D | Common Stock | 1,569 | 28.64 | 44.9K | 46,612 | — | ↗ |
| 2024-01-08 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 2,237 | 28.64 | 64.1K | 165,918 | — | ↗ |
| 2024-01-08 | Golden Lee Scott | Officer | S-Sale | D | Common Stock | 775 | 28.64 | 22.2K | 39,139 | — | ↗ |
| 2024-01-08 | Boulding Mark Elliott | Officer | S-Sale | D | Common Stock | 1,457 | 28.64 | 41.7K | 73,921 | — | ↗ |
| 2024-01-08 | Almstead Neil Gregory | Officer | S-Sale | D | Common Stock | 53 | 28.64 | 1.5K | 3,834 | — | ↗ |
| 2024-01-05 | Klein Matthew B. | Director / Officer | S-Sale | D | Common Stock | 10,107 | 27.15 | 274.4K | 168,155 | — | ↗ |
| 2023-12-28 | Klein Matthew B. | Director / Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 177,961 | — | ↗ |
| 2023-12-12 | Gravier Pierre | Officer | P-Purchase | A | Common Stock | 7,700 | 25.81 | 198.7K | 33,700 | — | ↗ |
| 2023-09-06 | Young Alethia | Director | S-Sale | D | Common Stock | 7,000 | 39.90 | 279.3K | 9,067 | — | ↗ |
| 2023-07-13 | Gravier Pierre | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 39.82 | 2.59M | 65,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
904.0K
Shares Outstanding
82.91M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Matthew B. Klein Chief Executive Officer | 958.5K | — | 16.59M | 4.40M | 1.29M | 20.3K | 23.27M | 90.23% | ↗ |
| 2 | 2025 | Eric Pauwels Chief Business Officer | 613.2K | — | 1.02M | 1.38M | 517.8K | 25.4K | 3.56M | 67.55% | ↗ |
| 3 | 2025 | Pierre Gravier Chief Financial Officer | 579.2K | — | 1.05M | 1.41M | 488.6K | 21.7K | 3.55M | 69.32% | ↗ |
| 4 | 2025 | Lee Golden Executive Vice President and Chief Medical Officer | 574.7K | — | 930.8K | 1.26M | 482.8K | 23.8K | 3.27M | 66.92% | ↗ |
| 5 | 2025 | Neil Almstead Chief Technical Operations Officer | 582.5K | — | 884.3K | 1.19M | 467.4K | 30.7K | 3.16M | 65.79% | ↗ |
| 6 | 2024 | Matthew B. Klein Chief Executive Officer | 882.2K | — | 3.00M | 2.36M | 1.15M | 19.6K | 7.41M | 72.32% | ↗ |
| 7 | 2024 | Eric Pauwels Chief Business Officer | 570.2K | — | 624.3K | 742.0K | 436.9K | 25.1K | 2.40M | 56.97% | ↗ |
| 8 | 2024 | Neil Almstead Chief Technical Operations Officer | 560.6K | — | 642.3K | 640.8K | 451.4K | 23.7K | 2.32M | 55.33% | ↗ |
| 9 | 2024 | Lee Golden Executive Vice President and Chief Medical Officer | 548.3K | — | 580.6K | 674.6K | 421.0K | 23.5K | 2.25M | 55.83% | ↗ |
| 10 | 2024 | Lee Golden Executive Vice President and Chief Medical Officer | 548.3K | — | 580.6K | 674.6K | 421.0K | 23.5K | 2.25M | 55.83% | ↗ |
| 11 | 2024 | Pierre Gravier Chief Financial Officer | 542.5K | — | 567.7K | 640.8K | 455.2K | 21.4K | 2.23M | 54.25% | ↗ |
| 12 | 2024 | Pierre Gravier Chief Financial Officer | 542.5K | — | 567.7K | 640.8K | 455.2K | 21.4K | 2.23M | 54.25% | ↗ |
| 13 | 2023 | Matthew B. Klein Chief Executive Officer | 747.2K | — | 4.55M | 3.15M | 472.8K | 19.3K | 8.94M | 86.13% | ↗ |
| 14 | 2023 | Matthew B. Klein Chief Executive Officer | 747.2K | — | 4.55M | 3.15M | 472.8K | 19.3K | 8.94M | 86.13% | ↗ |
| 15 | 2023 | Stuart W. Peltz, Ph.D. Former Chief Executive Officer | 188.0K | — | 2.09M | 2.77M | — | 608.9K | 5.66M | 85.92% | ↗ |
| 16 | 2023 | Pierre Gravier Chief Financial Officer | 245.0K | — | 1.04M | 1.36M | 94.5K | 1.6K | 2.73M | 87.53% | ↗ |
| 17 | 2023 | Pierre Gravier Chief Financial Officer | 245.0K | — | 1.04M | 1.36M | 94.5K | 1.6K | 2.73M | 87.53% | ↗ |
| 18 | 2023 | Pierre Gravier Chief Financial Officer | 245.0K | — | 1.04M | 1.36M | 94.5K | 1.6K | 2.73M | 87.53% | ↗ |
| 19 | 2023 | Eric Pauwels Chief Business Officer | 549.1K | — | 709.6K | 941.9K | 198.6K | 13.5K | 2.41M | 68.45% | ↗ |
| 20 | 2023 | Lee Golden Executive Vice President and Chief Medical Officer | 507.9K | — | 863.4K | 814.8K | 189.0K | 19.9K | 2.39M | 70.07% | ↗ |
| 21 | 2023 | Lee Golden Executive Vice President and Chief Medical Officer | 507.9K | — | 863.4K | 814.8K | 189.0K | 19.9K | 2.39M | 70.07% | ↗ |
| 22 | 2023 | Lee Golden Executive Vice President and Chief Medical Officer | 507.9K | — | 863.4K | 814.8K | 189.0K | 19.9K | 2.39M | 70.07% | ↗ |
| 23 | 2023 | Emily Hill Former Chief Financial Officer | 352.3K | — | 768.7K | 889.5K | — | 248.6K | 2.26M | 73.40% | ↗ |
| 24 | 2023 | Mark E Boulding Executive Vice President and Chief Legal Officer | 539.6K | — | 670.1K | 758.7K | 195.2K | 27.2K | 2.19M | 65.22% | ↗ |
| 25 | 2023 | Neil Almstead Chief Technical Operations Officer | 531.0K | — | 670.1K | 758.7K | 192.1K | 22.8K | 2.17M | 65.70% | ↗ |
| 26 | 2022 | Stuart W. Peltz, Ph.D. Chief Executive Officer | 791.8K | — | 1.68M | 3.95M | 720.6K | 28.1K | 7.16M | 78.50% | ↗ |
| 27 | 2022 | Stuart W. Peltz, Ph.D. Former Chief Executive Officer | 791.8K | — | 1.68M | 3.95M | 720.6K | 28.1K | 7.16M | 78.50% | ↗ |
| 28 | 2022 | Matthew B. Klein Chief Executive Officer | 598.4K | — | 1.56M | 2.45M | 379.5K | 17.5K | 5.01M | 80.13% | ↗ |
| 29 | 2022 | Matthew B. Klein Chief Executive Officer | 598.4K | — | 1.56M | 2.45M | 379.5K | 17.5K | 5.01M | 80.13% | ↗ |
| 30 | 2022 | Matthew B. Klein Chief Executive Officer | 598.4K | — | 1.56M | 2.45M | 379.5K | 17.5K | 5.01M | 80.13% | ↗ |
| 31 | 2022 | Eric Pauwels Chief Business Officer | 530.5K | — | 640.1K | 1.51M | 304.9K | 12.2K | 2.99M | 71.69% | ↗ |
| 32 | 2022 | Emily Hill Chief Financial Officer | 509.8K | — | 594.4K | 1.40M | 292.0K | 17.9K | 2.81M | 70.86% | ↗ |
| 33 | 2022 | Emily Hill Former Chief Financial Officer | 509.8K | — | 594.4K | 1.40M | 292.0K | 17.9K | 2.81M | 70.86% | ↗ |
| 34 | 2022 | Neil Almstead Chief Technical Operations Officer | 514.8K | — | 548.6K | 1.29M | 294.9K | 20.2K | 2.67M | 68.92% | ↗ |
| 35 | 2022 | Neil Almstead, Ph.D. Chief Technical Operations Officer | 514.8K | — | 548.6K | 1.29M | 294.9K | 20.2K | 2.67M | 68.92% | ↗ |
| 36 | 2022 | Mark E Boulding Executive Vice President and Chief Legal Officer | 523.1K | — | 548.6K | 1.29M | 272.4K | 21.8K | 2.66M | 69.25% | ↗ |
| 37 | 2021 | Stuart W. Peltz, Ph.D. Chief Executive Officer | 768.8K | — | 1.84M | 7.55M | 835.3K | 32.2K | 11.02M | 85.15% | ↗ |
| 38 | 2021 | Stuart W. Peltz, Ph.D. Former Chief Executive Officer | 768.8K | — | 1.84M | 7.55M | 835.3K | 32.2K | 11.02M | 85.15% | ↗ |
| 39 | 2021 | Emily Hill Former Chief Financial Officer | 489.5K | — | 718.1K | 2.95M | 312.1K | 12.7K | 4.49M | 81.85% | ↗ |
| 40 | 2021 | Emily Hill Chief Financial Officer | 489.5K | — | 718.1K | 2.95M | 312.1K | 12.7K | 4.49M | 81.85% | ↗ |
| 41 | 2021 | Mark E Boulding Executive Vice President and Chief Legal Officer | 503.9K | — | 678.2K | 2.79M | 298.7K | 21.5K | 4.29M | 80.80% | ↗ |
| 42 | 2021 | Mark E. Boulding Executive Vice President and Chief Legal Officer | 503.9K | — | 678.2K | 2.79M | 298.7K | 21.5K | 4.29M | 80.80% | ↗ |
| 43 | 2021 | Neil Almstead, Ph.D. Chief Technical Operations Officer | 496.6K | — | 678.2K | 2.79M | 294.3K | 19.9K | 4.28M | 81.05% | ↗ |
| 44 | 2021 | Eric Pauwels Chief Business Officer | 502.3K | — | 678.2K | 2.79M | 297.7K | 10.5K | 4.28M | 81.06% | ↗ |
| 45 | 2021 | Eric Pauwels Chief Business Officer | 502.3K | — | 678.2K | 2.79M | 297.7K | 10.5K | 4.28M | 81.06% | ↗ |
| 46 | 2020 | Stuart W. Peltz, Ph.D. Chief Executive Officer | 742.0K | — | 1.69M | 7.16M | 835.3K | 123.8K | 10.55M | 83.88% | ↗ |
| 47 | 2020 | Marcio Souza Former Chief Operating Officer | 171.0K | — | 644.6K | 3.58M | — | 6.9K | 4.40M | 95.96% | ↗ |
| 48 | 2020 | Eric Pauwels Chief Business Officer | 474.4K | — | 720.0K | 2.90M | 297.7K | 7.6K | 4.40M | 82.27% | ↗ |
| 49 | 2020 | Eric Pauwels Chief Business Officer | 474.4K | — | 720.0K | 2.90M | 297.7K | 7.6K | 4.40M | 82.27% | ↗ |
| 50 | 2020 | Eric Pauwels Chief Business Officer | 474.4K | — | 720.0K | 2.90M | 297.7K | 7.6K | 4.40M | 82.27% | ↗ |
| 51 | 2020 | Neil Almstead, Ph.D. Chief Technical Operations Officer | 481.8K | 4.6K | 521.8K | 2.59M | 294.3K | 16.8K | 3.91M | 79.58% | ↗ |
| 52 | 2020 | Emily Hill Chief Financial Officer | 458.3K | — | 475.8K | 2.41M | 312.1K | 12.1K | 3.67M | 78.69% | ↗ |
| 53 | 2020 | Emily Hill Chief Financial Officer | 458.3K | — | 475.8K | 2.41M | 312.1K | 12.1K | 3.67M | 78.69% | ↗ |
| 54 | 2020 | Mark E. Boulding Executive Vice President and Chief Legal Officer | 488.9K | — | 521.8K | 2.21M | 298.7K | 16.8K | 3.54M | 77.28% | ↗ |
| 55 | 2019 | Stuart W. Peltz, Ph.D. Chief Executive Officer | 702.0K | — | — | 6.32M | 724.0K | 16.8K | 7.76M | 81.41% | ↗ |
| 56 | 2019 | Stuart W. Peltz, Ph.D. Chief Executive Officer | 702.0K | — | — | 6.32M | 724.0K | 16.8K | 7.76M | 81.41% | ↗ |
| 57 | 2019 | Marcio Souza Former Chief Operating Officer | 528.0K | — | — | 2.81M | 363.0K | 7.9K | 3.71M | 75.77% | ↗ |
| 58 | 2019 | Marcio Souza Chief Operating Officer | 528.0K | — | — | 2.81M | 363.0K | 7.9K | 3.71M | 75.77% | ↗ |
| 59 | 2019 | Neil Almstead, Ph.D. Chief Technical Operations Officer | 468.0K | — | — | 1.78M | 257.4K | 16.8K | 2.52M | 70.53% | ↗ |
| 60 | 2019 | Neil Almstead, Ph.D. Chief Technical Operations Officer | 468.0K | — | — | 1.78M | 257.4K | 16.8K | 2.52M | 70.53% | ↗ |
| 61 | 2019 | Mark E. Boulding Executive Vice President and Chief Legal Officer | 475.0K | — | — | 1.78M | 237.5K | 20.9K | 2.51M | 70.78% | ↗ |
| 62 | 2019 | Mark E. Boulding Executive Vice President and Chief Legal Officer | 475.0K | — | — | 1.78M | 237.5K | 20.9K | 2.51M | 70.78% | ↗ |
| 63 | 2019 | Emily Hill Chief Financial Officer | 367.5K | — | 120.1K | 1.61M | 228.3K | 11.7K | 2.34M | 74.00% | ↗ |
| 64 | 2019 | Emily Hill Chief Financial Officer | 367.5K | — | 120.1K | 1.61M | 228.3K | 11.7K | 2.34M | 74.00% | ↗ |
| 65 | 2019 | Emily Hill Chief Financial Officer | 367.5K | — | 120.1K | 1.61M | 228.3K | 11.7K | 2.34M | 74.00% | ↗ |
| 66 | 2019 | Christine Utter Senior Vice President, Finance and Chief Accounting Officer | 387.4K | — | — | 1.10M | 193.5K | 14.7K | 1.70M | 64.97% | ↗ |
| 67 | 2018 | Stuart W. Peltz, Ph.D. Chief Executive Officer | 658.8K | — | — | 2.42M | 922.3K | 13.6K | 4.02M | 60.30% | ↗ |
| 68 | 2018 | Stuart W. Peltz, Ph.D. Chief Executive Officer | 658.8K | — | — | 2.42M | 922.3K | 13.6K | 4.02M | 60.30% | ↗ |
| 69 | 2018 | Marcio Souza Former Chief Operating Officer | 450.2K | 174.0K | — | 953.2K | 360.2K | 7.4K | 1.95M | 49.01% | ↗ |
| 70 | 2018 | Marcio Souza Chief Operating Officer | 450.2K | 174.0K | — | 953.2K | 360.2K | 7.4K | 1.95M | 49.01% | ↗ |
| 71 | 2018 | Neil Almstead, Ph.D. Chief Technical Operations Officer | 435.0K | — | — | 847.7K | 313.2K | 13.6K | 1.61M | 52.67% | ↗ |
| 72 | 2018 | Neil Almstead, Ph.D. Chief Technical Operations Officer | 435.0K | — | — | 847.7K | 313.2K | 13.6K | 1.61M | 52.67% | ↗ |
| 73 | 2018 | Mark E. Boulding Executive Vice President and Chief Legal Officer | 434.1K | — | — | 847.7K | 312.6K | 10.5K | 1.60M | 52.82% | ↗ |
| 74 | 2018 | Mark E. Boulding Executive Vice President and Chief Legal Officer | 434.1K | — | — | 847.7K | 312.6K | 10.5K | 1.60M | 52.82% | ↗ |
| 75 | 2018 | Christine Utter Principal Financial Officer and Treasurer | 360.0K | — | — | 515.3K | 259.2K | 14.3K | 1.15M | 44.85% | ↗ |
| 76 | 2018 | Christine Utter Senior Vice President, Finance and Chief Accounting Officer | 360.0K | — | — | 515.3K | 259.2K | 14.3K | 1.15M | 44.85% | ↗ |
| 77 | 2017 | Stuart W. Peltz, Ph.D. Chief Executive Officer | 636.5K | — | 242.6K | 974.4K | 302.4K | 16.8K | 2.17M | 56.01% | ↗ |
| 78 | 2017 | Marcio Souza Chief Operating Officer | 401.4K | 75.0K | 420.8K | 431.3K | 165.3K | 30.4K | 1.52M | 55.91% | ↗ |
| 79 | 2017 | Marcio Souza Chief Operating Officer | 401.4K | 75.0K | 420.8K | 431.3K | 165.3K | 30.4K | 1.52M | 55.91% | ↗ |
| 80 | 2017 | Mark E. Boulding Executive Vice President and Chief Legal Officer | 434.1K | 2.0K | 101.1K | 406.0K | 165.0K | 13.7K | 1.12M | 45.20% | ↗ |
| 81 | 2017 | Mark Rothera Former Chief Commercial Officer | 275.4K | — | 107.8K | 433.1K | — | 273.9K | 1.09M | 49.62% | ↗ |
| 82 | 2017 | Neil Almstead, Ph.D. Executive Vice President, Research, Pharmaceutical Operations Technology | 435.0K | — | 67.4K | 270.7K | 165.3K | 13.6K | 951.9K | 35.51% | ↗ |
| 83 | 2017 | Neil Almstead, Ph.D. Chief Technical Operations Officer | 435.0K | — | 67.4K | 270.7K | 165.3K | 13.6K | 951.9K | 35.51% | ↗ |
| 84 | 2017 | Christine Utter Principal Financial Officer and Treasurer | 317.6K | 25.0K | 43.8K | 315.7K | 142.1K | 26.6K | 870.7K | 41.28% | ↗ |
| 85 | 2017 | Christine Utter Principal Financial Officer and Treasurer | 317.6K | 25.0K | 43.8K | 315.7K | 142.1K | 26.6K | 870.7K | 41.28% | ↗ |
| 86 | 2017 | Shane Kovacs Former Executive Vice President, Chief Financial Officer and Head of Corporate Development | 189.4K | — | 101.1K | 406.0K | — | 11.2K | 707.7K | 71.65% | ↗ |
| 87 | 2016 | Stuart W. Peltz, Ph.D. Chief Executive Officer | 618.0K | — | — | 3.35M | 260.0K | 9.6K | 4.24M | 79.08% | ↗ |
| 88 | 2016 | Shane Kovacs Executive Vice President, Chief Financial Officer and Head of Corporate Development | 429.5K | — | — | 1.53M | 146.0K | 15.6K | 2.12M | 72.18% | ↗ |
| 89 | 2016 | Shane Kovacs Former Executive Vice President, Chief Financial Officer and Head of Corporate Development | 429.5K | — | — | 1.53M | 146.0K | 15.6K | 2.12M | 72.18% | ↗ |
| 90 | 2016 | Mark Rothera Former Chief Commercial Officer | 438.2K | — | — | 1.34M | 192.2K | 23.5K | 2.00M | 67.24% | ↗ |
| 91 | 2016 | Mark Rothera Chief Commercial Officer | 438.2K | — | — | 1.34M | 192.2K | 23.5K | 2.00M | 67.24% | ↗ |
| 92 | 2016 | Mark E. Boulding Executive Vice President and Chief Legal Officer | 421.5K | — | — | 1.34M | 143.3K | 14.5K | 1.92M | 69.85% | ↗ |
| 93 | 2016 | Mark E. Boulding Executive Vice President, Chief Legal Officer and Corporate Secretary | 421.5K | — | — | 1.34M | 143.3K | 14.5K | 1.92M | 69.85% | ↗ |
| 94 | 2016 | Neil Almstead, Ph.D. Executive Vice President, Research, Pharmaceutical Operations Technology | 422.3K | — | — | 1.05M | 143.6K | 8.6K | 1.63M | 64.73% | ↗ |
| 95 | 2016 | Neil Almstead, Ph.D. Chief Technical Operations Officer | 422.3K | — | — | 1.05M | 143.6K | 8.6K | 1.63M | 64.73% | ↗ |
| 96 | 2015 | Stuart W. Peltz, Ph.D. Chief Executive Officer | 600.0K | — | — | — | 310.0K | 8.2K | 10.52M | 0.00% | ↗ |
| 97 | 2015 | Shane Kovacs Executive Vice President, Chief Financial Officer and Head of Corporate Development | 417.0K | — | — | 2.74M | 187.7K | 14.0K | 3.36M | 81.58% | ↗ |
| 98 | 2015 | Shane Kovacs Former Executive Vice President, Chief Financial Officer and Head of Corporate Development | 417.0K | — | — | 2.74M | 187.7K | 14.0K | 3.36M | 81.58% | ↗ |
| 99 | 2015 | Shane Kovacs Executive Vice President, Chief Financial Officer and Head of Corporate Development | 417.0K | — | — | 2.74M | 187.7K | 14.0K | 3.36M | 81.58% | ↗ |
| 100 | 2015 | Mark E. Boulding Executive Vice President and Chief Legal Officer | 409.2K | — | — | 2.74M | 168.6K | 8.8K | 3.33M | 82.36% | ↗ |
| 101 | 2015 | Mark E. Boulding Executive Vice President, Chief Legal Officer and Corporate Secretary | 409.2K | — | — | 2.74M | 168.6K | 8.8K | 3.33M | 82.36% | ↗ |
| 102 | 2015 | Mark E. Boulding Executive Vice President, Chief Legal Officer and Corporate Secretary | 409.2K | — | — | 2.74M | 168.6K | 8.8K | 3.33M | 82.36% | ↗ |
| 103 | 2015 | Mark Rothera Chief Commercial Officer | 425.4K | — | — | 2.23M | 187.2K | 7.9K | 2.85M | 78.20% | ↗ |
| 104 | 2015 | Mark Rothera Former Chief Commercial Officer | 425.4K | — | — | 2.23M | 187.2K | 7.9K | 2.85M | 78.20% | ↗ |
| 105 | 2015 | Neil Almstead, Ph.D. Executive Vice President, Research, Pharmaceutical Operations Technology | 410.0K | 2.0K | — | 2.23M | 168.9K | 10.2K | 2.82M | 79.02% | ↗ |
| 106 | 2015 | Neil Almstead, Ph.D. Executive Vice President, Research, Pharmaceutical Operations Technology | 410.0K | 2.0K | — | 2.23M | 168.9K | 10.2K | 2.82M | 79.02% | ↗ |
| 107 | 2014 | Cláudia Hirawat Former President | 353.6K | — | 1.21M | 4.52M | 141.4K | 5.1K | 6.23M | 91.97% | ↗ |
| 108 | 2014 | Stuart W. Peltz, Ph.D. Chief Executive Officer | 495.0K | — | — | — | 445.5K | 5.3K | 5.00M | 0.00% | ↗ |
| 109 | 2014 | Robert Spiegel | 329.3K | — | — | 3.82M | 231.0K | 35.0K | 4.41M | 86.50% | ↗ |
| 110 | 2014 | Mark Rothera Chief Commercial Officer | 413.0K | — | — | 1.32M | 297.4K | 5.1K | 2.03M | 64.82% | ↗ |
| 111 | 2013 | Stuart W. Peltz, Ph.D. Chief Executive Officer | 460.8K | — | 2.00M | 5.21M | 290.0K | 7.5K | 7.96M | 90.48% | ↗ |
| 112 | 2013 | Cláudia Hirawat Former President | 316.2K | — | 530.1K | 1.15M | 195.8K | 3.1K | 2.19M | 76.51% | ↗ |
| 113 | 2013 | Claudia Hirawat President | 316.2K | — | 530.1K | 1.15M | 195.8K | 3.1K | 2.19M | 76.51% | ↗ |
| 114 | 2013 | Mark A. Rothera Chief Commercial Officer | 300.0K | 68.2K | — | 1.36M | 211.2K | 128.7K | 2.07M | 65.83% | ↗ |
| 115 | 2012 | Stuart W. Peltz, Ph.D. Chief Executive Officer | 446.3K | — | — | 67.2K | 204.8K | 4.4K | 722.6K | 9.30% | ↗ |
| 116 | 2012 | Claudia Hirawat President | 281.0K | — | — | 30.9K | 83.6K | 56.7K | 452.2K | 6.83% | ↗ |
| 117 | 2012 | Mark A. Rothera Chief Commercial Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Matthew Klein | Chief Executive Officer & Director | 2M | — |
| Eric Pauwels | Chief Business Officer | 1M | male |
| Pierre Gravier | Chief Financial Officer | 1M | male |
| Lee Golden | Executive Vice President & Chief Medical Officer | 1M | — |
| Neil Almstead | Chief Technical Operations Officer | 1M | — |
| Mark Elliott Boulding | Executive Vice President & Chief Legal Officer | 761.9K | male |
| Christine Utter | Senior Vice President, Chief Accounting Officer & Head of People Services | 595.5K | female |
| Allan Steven Jacobson | Co-Founder & Independent Director | 140.0K | — |
| Linda Montella Carter | Senior Vice President & Chief Information Officer | — | female |
| Ellen Cavaleri | Head of Investor Relations | — | female |
| Jane Baj | Vice President of Corporate Communications | — | female |
| Hege Sollie-Zetlmayer | Chief Human Resources Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PTCT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
